地拉罗司在中国上市了没？

Deferasirox (deferasirox) was developed by Novartis and is a commonly used drug to relieve iron accumulation. Deferasirox (Enrig, Deferasirox) is very effective. It plays a good auxiliary role in patients with thalassemia or other rare anemias that require long-term blood transfusions that lead to iron accumulation (people who require long-term blood transfusions (blood transfusion volume up to 100 ml/kg) and whose serum ferritin exceeds 1000 μg/L). So, has Deferasirox been launched in China?

Deferasirox was the first oral iron chelator approved by the FDA for routine use in 2005 and is now available in more than 80 countries. In 2010, Deferasirox (deferasirox) was approved for marketing in China for the treatment of chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥ 7 mL/kg) in beta-thalassemia patients older than 6 years old. For iron overload caused by children under 6 years old and other transfusion-dependent diseases, Deferasirox has limited safety and efficacy data for Chinese patients, and it is recommended to use it with caution based on the specific conditions of the patients.

Indications for Deferasirox:

1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop symptoms of chronic iron overload when serum ferritin continues to be >1000 L. At this time, iron chelation therapy should be started. 

2. Patients receiving ASCT can also be given iron chelator treatment when iron overload occurs;

3. Deferasirox can be used to treat reversible renal insufficiency caused by Fanconi syndrome!

Deferasirox (Deferasirox) may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication; if the condition is severe or persistent, the medication should be stopped. The patient's vision or hearing may be affected. It should be taken 30 minutes before meals. It should be taken at the same time every day. Deferasirox (Deferasirox) should not be taken at the same time as drugs containing aluminum (such as gastric acid neutralizers).

While taking the drug Deferasirox, patients with thalassemia are often physically weak, so they should live cautiously, adapt to cold temperatures, and pay attention to preventing external infections; engage in more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to enhance physical fitness and disease resistance.

The above is the content of (Enrig, Deferasirox) listing, I hope it can help you!